These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20739654)

  • 21. FDA approval of nevirapine for HIV.
    Am Fam Physician; 1996 Oct; 54(5):1805-6. PubMed ID: 8857799
    [No Abstract]   [Full Text] [Related]  

  • 22. FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients.
    AIDS Alert; 2009 Sep; 24(9):106-7. PubMed ID: 19938313
    [No Abstract]   [Full Text] [Related]  

  • 23. Postmarketing modifications in the safety labeling of the new antiepileptics.
    Buck ML; Gurka MJ; Goodkin HP
    Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
    [No Abstract]   [Full Text] [Related]  

  • 24. FDA advisory panel voices persistent safety concerns.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Apr; 98(7):439. PubMed ID: 16595778
    [No Abstract]   [Full Text] [Related]  

  • 25. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness--FDA. Proposed rule.
    Fed Regist; 1998 Oct; 63(195):54082-9. PubMed ID: 10185826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 27. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
    Kane RC; Farrell AT; Sridhara R; Pazdur R
    Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Consumer groups look to improve adverse event reporting systems.
    Vastag B
    J Natl Cancer Inst; 2005 Dec; 97(24):1804-5. PubMed ID: 16368939
    [No Abstract]   [Full Text] [Related]  

  • 29. 3TC receives full approval.
    Grodeck B; Vazquez E
    Posit Aware; 1997; 8(3):11. PubMed ID: 11364417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Policy currents. FDA addresses backlog of generic medication applications.
    Consult Pharm; 2006 May; 21(5):419-21. PubMed ID: 16929569
    [No Abstract]   [Full Text] [Related]  

  • 31. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
    Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA guidance document on monitoring delayed adverse events a good first start.
    Williams DA
    Mol Ther; 2005 Dec; 12(6):991-2. PubMed ID: 16271514
    [No Abstract]   [Full Text] [Related]  

  • 33. FDA notifications. FDA postpones CCR5 Antagonist Review Group meeting.
    AIDS Alert; 2006 Jan; 21(1):11-2. PubMed ID: 16470945
    [No Abstract]   [Full Text] [Related]  

  • 34. Tuft's report backs FDA fast-track, but post-marketing concerns loom.
    Vastag B
    Nat Biotechnol; 2006 May; 24(5):478. PubMed ID: 16680113
    [No Abstract]   [Full Text] [Related]  

  • 35. Postmarketing surveillance for oncology drugs.
    Viale PH; Moore S
    Clin J Oncol Nurs; 2008 Dec; 12(6):877-86. PubMed ID: 19064381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer drugs remain FDA approved despite lack of benefit, study finds.
    McCarthy M
    BMJ; 2016 Dec; 355():i6568. PubMed ID: 27923801
    [No Abstract]   [Full Text] [Related]  

  • 37. FDA set to tighten guidelines on industry dissemination of information on unapproved uses of medical products.
    Lang L
    Gastroenterology; 2008 Apr; 134(4):905. PubMed ID: 18395067
    [No Abstract]   [Full Text] [Related]  

  • 38. FDA warns sellers of nicotine lollipops, lip balm.
    FDA Consum; 2002; 36(4):5-6. PubMed ID: 12184310
    [No Abstract]   [Full Text] [Related]  

  • 39. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
    Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Vioxx debacle revisited.
    Mohapatra PR; Janmeja AK
    Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.